Unio Capital’s Edwards Lifesciences EW Stock Holding History

Unio Capital’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-5,400	Closed	-$262K	–	76
2018 Q2	$262K	Buy	+5,400	New	+$252K	0.2%	60

Other funds holding EW

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Unio Capital's EW Position: Q2 2019 in Review

Unio Capital sold out of Edwards Lifesciences (EW) in Q2 2019, closing a stake of 5,400 shares — an estimated $344K sold.

Unio Capital first reported a position in EW in Q4 2017 and held it in 5 quarters. The position peaked at $344K in Q1 2019. 921 funds tracked by Wall St. Rank hold EW as of Q2 2019.

Unio Capital reported no remaining Edwards Lifesciences position as of Q2 2019 after selling out during the quarter.
Unio Capital sold 5,400 Edwards Lifesciences shares in Q2 2019, an estimated $344K.
Unio Capital first reported a position in Edwards Lifesciences in Q4 2017 and held it in 5 quarters.
Unio Capital's Edwards Lifesciences position peaked at $344K in Q1 2019.
921 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2019.

Based on Unio Capital's 13F filing for Q2 2019, filed 14 Aug 2019.